GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » Cash Flow from Investing

Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Cash Flow from Investing : $74.23 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Eiger BioPharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $12.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Eiger BioPharmaceuticals gained $12.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Eiger BioPharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Eiger BioPharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals Cash Flow from Investing Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.47 -44.79 61.53 9.63 74.23

Eiger BioPharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.80 13.38 29.85 19.00 12.00

Eiger BioPharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Eiger BioPharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Eiger BioPharmaceuticals's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $74.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eiger BioPharmaceuticals  (OTCPK:EIGRQ) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Eiger BioPharmaceuticals's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.00 Mil. It means Eiger BioPharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Eiger BioPharmaceuticals's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Eiger BioPharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Eiger BioPharmaceuticals's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Eiger BioPharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Eiger BioPharmaceuticals's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Eiger BioPharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Eiger BioPharmaceuticals's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Eiger BioPharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Eiger BioPharmaceuticals's sale of investment for the three months ended in Dec. 2023 was $12.00 Mil. It means Eiger BioPharmaceuticals gained $12.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Eiger BioPharmaceuticals's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Eiger BioPharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Eiger BioPharmaceuticals's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Eiger BioPharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Eiger BioPharmaceuticals's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Eiger BioPharmaceuticals paid $0.00 Mil for other investing activities.


Eiger BioPharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description

Traded in Other Exchanges
Address
2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Executives
Richard A Kayne 10 percent owner
Leen Kawas 10 percent owner 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong officer: Chief Business Officer 24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff officer: CFO 4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins officer: General Counsel C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii officer: Ex VP & Chief Commerc. Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn director 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian director C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson officer: GC & Chief Compliance Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory director, officer: President and CEO 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306